未知生产厂商
FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute. It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. (COVID-19) - SOBERANA 01).
FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute. It is currently being tested in the clinical trial RPCEC00000332 (Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. (COVID-19) - SOBERANA 01).
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
